Amended Current Report Filing (8-k/a)

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 8-K/A

CURRENT REPORT

Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934

Date of Report (Date of earliest event reported) – April 29, 2021


WEST PHARMACEUTICAL SERVICES, INC.

(Exact name of registrant as specified in its charter)

Pennsylvania

1-8036

23-1210010

(State or other jurisdiction

of incorporation)

(Commission File Number)

(IRS Employer

Identification No.)

530 Herman O. West Drive, Exton, PA

19341-0645

(Address of principal executive offices)

(Zip Code)

Registrant’s telephone number, including area code: 610-594-2900


Not Applicable
(Former name or address, if changed since last report.)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):


☐			Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)


☐			Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)


☐			Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))


☐			Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:


Title of each class	Trading Symbol	Name of each exchange on which registered
Common Stock, par value $0.25 per share	WST	New York Stock Exchange

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

Emerging growth company ☐

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

Explanatory Note:

This Form 8-K/A is being filed solely to correct a clerical error in the table entitled Reconciliation of Net Sales to Organic Net Sales in the Company’s press release and presentation, each dated April 29, 2021 which is on page 8 of Exhibit 99.1 and page 19 of Exhibit 99.2. The corrected table is filed with this Form 8-K/A and contains the corrected total for the effect of changes in currency translation rates.

The Company has not made any other changes to the information furnished with the original 8-K.

Item 9.01 Financial Statements and Exhibits.


(d)	Exhibit No.	Description
	99.1	West Pharmaceutical Services, Inc. Corrected Press Release, dated April 29, 2021.
	99.2	West Pharmaceutical Services, Inc. Corrected Presentation, dated April 29, 2021.
	104	The cover page from the Company’s Current Report on Form 8-K/A, dated April 29, 2021, formatted in Inline XBRL.

SIGNATURE

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.


			WEST PHARMACEUTICAL SERVICES, INC.


			/s/ Bernard J. Birkett
			Bernard J. Birkett
			Senior Vice President and Chief Financial Officer


April 29, 2021

EXHIBIT INDEX


Exhibit No.						Description
99.1						West Pharmaceutical Services, Inc. Corrected Press Release, dated April 29, 2021.
99.2						West Pharmaceutical Services, Inc. Corrected Presentation, dated April 29, 2021.
104						The cover page from the Company’s Current Report on Form 8-K/A, dated April 29, 2021, formatted in Inline XBRL.